TearLab Stock Forecast, Price & News

0.00 (-1.86 %)
(As of 07/9/2020)
Today's Range
Now: $0.06
50-Day Range
MA: $0.06
52-Week Range
Now: $0.06
Volume20,200 shs
Average Volume97,724 shs
Market Capitalization$727,281.90
P/E RatioN/A
Dividend YieldN/A
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
TearLab logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:TEAR
Previous SymbolNASDAQ:TEAR
Year FoundedN/A



Sales & Book Value

Annual Sales$22.66 million
Book Value($2.07) per share



Market Cap$727,281.90
Next Earnings Date6/25/2021 (Estimated)
OptionableNot Optionable


News for Adcare Health Systems Inc
December 3, 2020 |  markets.businessinsider.com
Financials Sushiro Global
October 1, 2020 |  markets.businessinsider.com
TearLab: 1Q Earnings Snapshot
June 26, 2020 |  ca.finance.yahoo.com
TearLab Corp.
May 10, 2020 |  www.marketwatch.com
TearLab Corporation Confirms Merger Discussions
May 7, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.60 out of 5 stars

Medical Sector

1373rd out of 2,025 stocks

Surgical & Medical Instruments Industry

126th out of 169 stocks

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
0.00 (-1.86 %)
(As of 07/9/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive TEAR News and Ratings via Email

Sign-up to receive the latest news and ratings for TEAR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

TearLab (OTCMKTS:TEAR) Frequently Asked Questions

What stocks does MarketBeat like better than TearLab?

Wall Street analysts have given TearLab a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TearLab wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TearLab's next earnings date?

TearLab is scheduled to release its next quarterly earnings announcement on Friday, June 25th 2021.
View our earnings forecast for TearLab

How were TearLab's earnings last quarter?

TearLab Co. (OTCMKTS:TEAR) issued its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter. The medical research company earned $5.85 million during the quarter.
View TearLab's earnings history

How has TearLab's stock been impacted by COVID-19 (Coronavirus)?

TearLab's stock was trading at $0.0312 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TEAR stock has increased by 85.6% and is now trading at $0.0579.
View which stocks have been most impacted by COVID-19

When did TearLab's stock split? How did TearLab's stock split work?

Shares of TearLab reverse split before market open on Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 23rd 2017. An investor that had 100 shares of TearLab stock prior to the reverse split would have 10 shares after the split.

Who are TearLab's key executives?

TearLab's management team includes the following people:
  • Mr. Elias Vamvakas, Exec. Chairman & Sec. (Age 60)
  • Mr. Joseph S. Jensen, CEO & Director (Age 47)
  • Mr. Michael Marquez, Chief Financial Officer (Age 37)
  • Dr. Benjamin Sullivan Ph.D., Chief Scientific Officer (Age 43)
  • Mr. Sam Fakhoury, VP of Quality, Compliance & Supply Chain

Who are some of TearLab's key competitors?

What other stocks do shareholders of TearLab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TearLab investors own include Vertex Energy (VTNR), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), CorMedix (CRMD), (SPHS), Verastem (VSTM), Biocept (BIOC) and MEI Pharma (MEIP).

What is TearLab's stock symbol?

TearLab trades on the OTCMKTS under the ticker symbol "TEAR."

How do I buy shares of TearLab?

Shares of TEAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TearLab's stock price today?

One share of TEAR stock can currently be purchased for approximately $0.06.

How much money does TearLab make?

TearLab has a market capitalization of $727,281.90 and generates $22.66 million in revenue each year.

How many employees does TearLab have?

TearLab employs 34 workers across the globe.

What is TearLab's official website?

The official website for TearLab is www.tearlab.com.

Where are TearLab's headquarters?

TearLab is headquartered at 150 La Terraza Blvd. Suite 101, Escondido CA, 92025.

How can I contact TearLab?

TearLab's mailing address is 150 La Terraza Blvd. Suite 101, Escondido CA, 92025. The medical research company can be reached via phone at 858-455-6006 or via email at [email protected]

This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.